Improved Lipid Profile Associated with Daily Consumption of Tri-Sura-Phon in Healthy Overweight Volunteers: An Open-Label, Randomized Controlled Trial
Table 3
Changes in clinical laboratory parameters after the consumption of Tri-Sura-Phon tea.
Parameters
Tested groups
Changes of evaluated values (SD)
wk. 0 versus wk. 4th
wk. 0 versus wk. 8th
wk. 4th versus wk. 8th
BMI (kg/m2)
Tri-Sura-Phon
0.1 (0.4)3
0.1 (0.5)3
0.0 (0.3)1
Placebo
0.3 (0.5)
0.1 (0.7)
−0.2 (0.5)
Total cholesterol (mg/dL)
Tri-Sura-Phon
10.1 (34.0)
22.4 (42.4)1,2,3
12.2 (22.3)
Placebo
−3.2 (33.2)
−1.5 (29.8)
1.7 (29.6)
Triglycerides (mg/dL)
Tri-Sura-Phon
68.2 (79.3)1,3
44.1 (80.8)
−24.1 (47.3)
Placebo
16.8 (97.7)
46.3 (76.5)
29.5 (57.7)
Low density lipoprotein (mg/dL)
Tri-Sura-Phon
0.9 (38.8)
22.1 (49.2)
21.18 (26.7)
Placebo
−8.9 (36.0)
−15.5 (38.9)
−6.7 (35.2)
High density lipoprotein (mg/dL)
Tri-Sura-Phon
−4.6 (13.3)2,3
−9.0 (15.3)1,2,3
−4.4 (11.8)2,3
Placebo
−1.8 (12.6)
4.9 (12.7)
6.7 (14.9)
FBG (mg/dL)
Tri-Sura-Phon
−7.8 (7.8)3
8.1 (7.0)3
−0.3 (7.2)
Placebo
−10.0 (7.7)
−9.7 (8.1)
0.2 (8.3)
Insulin level (uU/mL)
Tri-Sura-Phon
0.5 (4.0)
−1.0 (4.6)
−1.7 (4.4)
Placebo
−0.2 (5.9)
−2.4 (8.2)
−2.0 (7.7)
Albumin (gm/dL)
Tri-Sura-Phon
0.1 (0.4)3
0.4 (0.7)
0.1 (0.5)
Placebo
0.2 (0.5)
0.0 (0.2)
−0.3 (0.5)
Total bilirubin (mg/dL)
Tri-Sura-Phon
0.0 (0.2)
0.0 (0.0)2,3
0.1 (0.3)
Placebo
0.0 (0.2)
0.1 (0.3)
0.1 (0.4)
Direct bilirubin (mg/dL)
Tri-Sura-Phon
0.0 (0.0)
0.0 (0.0)
0.0 (0.0)
Placebo
0.0 (0.2)
0.0 (0.2)
0.0 (0.0)
AST (U/L)
Tri-Sura-Phon
−2.5 (7.2)
0.2 (5.3)
2.8 (5.2)
Placebo
−1.5 (7.4)
−1.6 (9.8)
−0.1 (13.4)
ALT (U/L)
Tri-Sura-Phon
0.3 (10.2)2,3
2.3 (11.4)2,3
2.0 (7.7)2,3
Placebo
1.8 (8.9)
−7.9 (24.1)
−9.7 (23.9)
ALP (U/L)
Tri-Sura-Phon
2.1 (9.3)
8.6 (12.4)
6.4 (11.2)
Placebo
2.7 (15.1)
3.0 (11.4)
0.36 (16.8)
GGT (U/L)
Tri-Sura-Phon
−0.7 (9.4)
−0.1 (8.7)
0.6 (4.1)
Placebo
2.5 (5.1)
−0.5 (8.5)
−3.0 (9.6)
Uppercase superscript letters indicate significant differences in changes of parameters between baseline and week 4 (A) or baseline and week 8 (B) or weeks 4 and 8 (C) in the same treatment. Superscript numbers indicate significant differences in changes of parameters between baseline and week 4 (1) or baseline and week 8 (2) or weeks 4 and 8 (3) among the treatments. Negative values correspond to increases from baseline and positive values correspond to decreases from baseline. BMI = body mass index, FBG = fasting blood glucose, AST = aspartate aminotransferase, ALT = alanine aminotransferase, ALP = alkaline phosphatase, and GGT = gamma-glutamyl transpeptidase.
